References
1. Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical Practice
Guideline for the Management of Infantile
Hemangiomas. Pediatrics . 2019;143:e20183475.
2. Munden A, Butschek R, Tom WL, et al. Prospective study of infantile
haemangiomas: incidence, clinical characteristics and association with
placental anomalies. Br J Dermatol . 2014;170:907-13.
3. Leaute-Labreze C, Harper JI, Hoeger PH. Infantile haemangioma.Lancet . 2017;390:85-94.
4. Luu M, Frieden IJ. Haemangioma: clinical course, complications and
management. Br J Dermatol . 2013;169:20-30.
5. Shayan YR, Prendiville JS, Goldman RD. Use of propranolol in treating
hemangiomas. Can Fam Physician . 2011;57:302-303.
6. Leaute-Labreze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized,
controlled trial of oral propranolol in infantile hemangioma. N
Engl J Med . 2015;372:735-46.
7. Marqueling AL, Oza V, Frieden IJ, Puttgen KB. Propranolol and
infantile hemangiomas four years later: a systematic review.Pediatr Dermatol . 2013;30:182-91.
8. Harris J, Phillips JD. Evaluating the Clinical Outcomes of Parotid
Hemangiomas in the Pediatric Patient Population. Ear Nose Throat
J . 2021;100:NP242-NP245.
9. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo
JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl
J Med . 2008;358:2649-5.
10. Rosenberg TL, Phillips JD. Update on Vascular Anomalies of the Head
and Neck. Otolaryngol Clin North Am . 2022;55:1215-1231.
11. Lee JW, Chung HY. Vascular anomalies of the head and neck: current
overview. Arch Craniofac Surg . 2018;19:243-247.
12. Puttgen KB. Diagnosis and management of infantile hemangiomas.Pediatr Clin North Am . 2014;61:383-402.
13. Mariani LG, Ferreira LM, Rovaris DL, Bonamigo RR, Kiszewski AE.
Infantile hemangiomas: risk factors for complications, recurrence and
unaesthetic sequelae. An Bras Dermatol . 2022;97:37-44.
14. Demartini Z, Jr., Gatto LAM, Lages RO, Francisco AN, Maeda AK, Koppe
GL. Atypical Presentation of PHACE Syndrome: Hidden Facial Hemangioma.Pediatr Neurosurg . 2018;53:421-426.
15. Haggstrom AN, Garzon MC, Baselga E, et al. Risk for PHACE syndrome
in infants with large facial hemangiomas. Pediatrics .
2010;126:e418-26.
16. Parikh SR, Darrow DH, Grimmer JF, Manning SC, Richter GT, Perkins
JA. Propranolol use for infantile hemangiomas: American Society of
Pediatric Otolaryngology Vascular Anomalies Task Force practice
patterns. JAMA Otolaryngol Head Neck Surg . 2013;139:153-156.
17. Chinnadurai S, Sathe NA, Surawicz T. Laser treatment of infantile
hemangioma: A systematic review. Lasers Surg Med . 2016;48:221-33.
18. Beqo BP, Gasparella P, Flucher C, Spendel S, Quehenberger F, Haxhija
EQ. Indications for surgical resection of complicated infantile
hemangiomas in the beta-blocker’s era: a single-institution experience
from a retrospective cohort study. Int J Surg . 2023;109:829-840.
19. Chang L, Lv D, Yu Z, et al. Infantile hemangioma: factors causing
recurrence after propranolol treatment. Pediatr Res . Jan
2018;83:175-182.
20. Wu Y, Zhao P, Song W, Lu W, Dai T, Wang L. Our experience with
propranolol for infantile hemangioma. Skin Res Technol .
2023;29:e13310.
21. Frongia G, Byeon JO, Mehrabi A, Gunther P. Recurrence rate of
infantile hemangioma after oral propranolol therapy. Eur J
Pediatr . 2021;180:585-590.
22. Chang L, Ma G, Jin Y, et al. Recurrence of infantile hemangioma
after termination of propranolol treatment. Ann Plast Surg .
2014;72(2):173-5.